Nicolas Hubacz: A New Target for Stroke Recovery
Nicolas Hubacz, Research and Clinical Products Business Development Manager at Magstim, shared a post on LinkedIn about a recent article by Yan Deng et al. published in Science Signaling, adding:
”A New Target for Stroke Recovery
Stroke treatment has made tremendous progress in restoring blood flow, but many survivors are still left with lasting white matter damage, a major cause of long-term neurological disability.
A new study published in Science Signaling identifies the adenosine 2A receptor (A2AR) on microglia as a key regulator of white matter repair after ischemic stroke in mice.
The researchers found that:
- Microglia lacking A2AR showed impaired white matter regeneration after stroke, despite having similar initial injury severity.
- Activating A2AR using blood-brain barrier–permeable agonist micelles during early reperfusion enhanced remyelination and improved both cognitive and sensorimotor recovery in mice.
- A2AR activation promoted efferocytosis, allowing microglia to clear apoptotic cells and myelin debris, helping reduce secondary inflammation and create an environment that supports remyelination.
- Mechanistically, A2AR signaling triggered HIF1α-dependent metabolic reprogramming, increasing glycolysis to provide the energy needed for sustained debris clearance.
While these findings are currently limited to preclinical models, they identify microglial A2AR signaling as a potential therapeutic target for promoting white matter repair and improving functional recovery after stroke.
Paper: Adenosine 2A receptor drives microglial efferocytosis to accelerate white matter repair and functional recovery after stroke (Science Signaling, 2026)”
Title: Adenosine 2A receptor drives microglial efferocytosis to accelerate white matter repair and functional recovery after stroke
Authors: Yan Deng, Qian He, Bolin Yao, Xiang Chen, Guangli Cheng, Minhua Xu, Jiachun Hu, Luis Graca, Xiao Zhu, Xiao-Yong Zhang, Yan You, Cong Li.
Other posts featuring Nicolas Hubacz on Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention